The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.

Theodore Mazzone, Michael Davidson, Tamar Polonsky

Journal: Trends in cardiovascular medicine 2009;19(3):94-9

PMID: 19679266

Full Text on Elsevier Science View on PubMed

Abstract

The CHICAGO study (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) tested the hypothesis that pioglitazone would have a beneficial effect for reducing CIMT progression, compared with glimepiride. Treatment with pioglitazone produced improvement in several parameters, such as systolic blood pressure and lipid levels, including a 14% increase in HDL cholesterol, and reduced CIMT progression, compared with glimepiride. However, only the beneficial effect on HDL cholesterol predicted its beneficial effect for reducing CIMT progression. The following review examines data from additional studies evaluating how pioglitazone and HDL levels modify cardiovascular risk.

Address: Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA.

DOI: 10.1016/j.tcm.2009.06.002

Link outs

Free resources

Medical:

https://medlineplus.gov/diabetestype2.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Carotid Arteries, Chicago, Cholesterol, HDL, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Hypoglycemic Agents, Pioglitazone, Randomized Controlled Trials as Topic, Sulfonylurea Compounds, Thiazolidinediones, Tunica Intima